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Background: A common approach to cancer therapy in clinical practice is the combination of several drugs to
boost the anticancer activity of available drugs while suppressing their unwanted side effects. In this regard, we
examined the efficacy of combination treatment with the widely-used genotoxic drug doxorubicin and the
mitochondriotoxic Hsp90 inhibitor gamitrinib to exploit disparate stress signaling pathways for cancer therapy.
Methods: The cytotoxicity of the drugs as single agents or in combination against several cancer cell types was
analyzed by MTT assay and the synergism of the drug combination was evaluated by calculating the combination
index. To understand the molecular mechanism of the drug synergism, stress signaling pathways were analyzed
after drug combination. Two xenograft models with breast and prostate cancer cells were used to evaluate
anticancer activity of the drug combination in vivo. Cardiotoxicity was assessed by tissue histology and serum
creatine phosphokinase concentration.
Results: Gamitrinib sensitized various human cancer cells to doxorubicin treatment, and combination treatment
with the two drugs synergistically increased apoptosis. The cytotoxicity of the drug combination involved activation
and mitochondrial accumulation of the proapoptotic Bcl-2 family member Bim. Activation of Bim was associated
with increased expression of the proapoptotic transcription factor C/EBP-homologous protein and enhanced
activation of the stress kinase c-Jun N-terminal kinase. Combined drug treatment with doxorubicin and gamitrinib
dramatically reduced in vivo tumor growth in prostate and breast xenograft models without increasing
cardiotoxicity.
Conclusions: The drug combination showed synergistic anticancer activities toward various cancer cells without
aggravating the cardiotoxic side effects of doxorubicin, suggesting that the full therapeutic potential of doxorubicin
can be unleashed through combination with gamitrinib.Background
Heat shock protein 90 (Hsp90) is an ATP-dependent
molecular chaperone that controls folding of a wide
range of protein substrates, or clients, many of which
are involved in signal pathways crucial for tumorigenesis
[1,2]. The primary cellular location of Hsp90 is the cyto-
plasm, but a pool of Hsp90 and its isoform, tumor ne-
crosis factor receptor-associated protein 1 (TRAP1), has
been reported in mitochondria [3,4]. The mitochondrial
expression of Hsp90 and TRAP1 is often elevated in
many cultured cancer cells and human cancer patients* Correspondence: kangbh@unist.ac.kr
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unless otherwise stated.[3,5,6]. These proteins play important roles in multistep
tumorigenic processes including the neoplastic meta-
bolic shift to aerobic glycolysis [7-9] and inhibition of
cell death [3].
A class of mitochondriotropic Hsp90 inhibitors, named
gamitrinibs (GA mitochondrial matrix inhibitors), has
been developed through combinatorial chemistry [10].
Gamitrinibs consist of geldanamycin, a competitive in-
hibitor of the ATPase pocket of Hsp90 and TRAP1, con-
jugated with tandem repeats of tetracyclic guanidinium
or triphenylphosphonium for mitochondrial targeting
[10,11]. Gamitrinibs not only trigger massive cell death
in cultured cancer cells in vitro but also strongly suppress
tumor growth in various xenograft and genetic mouse. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cytotoxicity is attributed to the reactivation of cyclophilin
D (Cyp-D), an opener of the permeability transition pore
(PTP) located in the mitochondrial inner membrane
[3,14]. Because such opening of the PTP can be lethal,
Cyp-D activation is often suppressed in cancer cells by
interaction with mitochondrial Hsp90s, which increase
resistance to various cellular stresses [3]. In addition,
gamitrinibs have been shown to induce organelle-specific
stress responses and dysregulation of bioenergetics in
mitochondria of cancer cells, concomitantly compromis-
ing neoplastic growth [9,15-17].
Doxorubicin (DOX), an anthracycline antibiotic with
the trade name Adriamycin, is one of the most effective
anticancer drugs and has been widely used in various
chemotherapeutic regimens to treat patients with cancer
[18]. The antitumor activities of DOX are primarily at-
tributed to DNA damage resulting from the inhibition of
DNA topoisomerase II [18,19]. The clinical use of DOX,
however, has been limited by the risk of cardiotoxicity,
which is dependent on the cumulative dose/treatment
schedule, typically refractory to common medications,
and can be fatal [20-22].
Here, we examined whether a combination of two
cytotoxic drugs with unrelated action mechanisms, DOX
(genotoxic) and gamitrinib (mitochondriotoxic), would
exhibit enhanced anticancer activity without aggravating
unwanted side effects. This drug combination showed
synergistically increased anticancer activities in vitro and
in vivo, without augmenting cardiomyocyte toxicity. The
underlying mechanism of action involved the activation
of a proapoptotic Bcl-2 protein following the stimulation
of CHOP and JNK pathways in cancer cells.
Methods
Chemicals and antibodies
Gamitrinib conjugated with triphenylphosphonium was
prepared as described previously [10]. MitoTracker, JC-
1, and tetramethylrhodamine methyl ester (TMRM)
were purchased from Molecular Probes. All other che-
micals were purchased from Sigma.
The following antibodies were used in this study: anti-
JNK, anti-phospho-JNK (Thr183/Tyr185), anti-COX-IV,
and anti-CHOP from Cell Signaling Technology; anti-
cytochrome c, anti-Bim, and anti-PARP from Santa Cruz
Biotechnology; anti-β-actin from MP Biomedicals; and
anti-TRAP1, anti-Bax, anti-caspase-8, and anti-caspase-3
from BD Biosciences.
Cells and cell culture
Human cancer cell types that originated from ovary (SK-
OV3), prostate (22Rv1 and PC3), cervix (HeLa), breast
(MDA-MB-231), liver (SK-HEP-1), brain (A172), kidney
(ACHN), and lung (NCI-H460) were purchased fromthe Korean Cell Line Bank. Cells were cultured in
DMEM or RPMI (GIBCO) medium containing 10% FBS
(GIBCO) and 1% penicillin/streptomycin (GIBCO) at
37°C in a 10% CO2 humidified atmosphere.
siRNA treatment
Small interfering RNAs (siRNAs) against JNK and CHOP
were synthesized by Genolution Inc (Korea). siRNA se-
quences used in this study were as follows:
JNK1-#1, 5′-AAAGAATGTCCTACCTTCTCT-3′; JN
K1-#2, 5′-AAGCCCAGTAATATAGTAGTA-3′; CHOP-
#1, 5′-AGAACCAGCAGAGGTCACAA-3′; CHOP-#2,
5′-AAGAGAATGAACGGCTCAAGC-3′; Bim-#1, 5′-GC
AACCTTCTGATGTAAGT-3′; Bim-#2, 5′-GACCGAGAA
GGTAGACAATT-3′ and control, 5′-ACUCUAUCUGCA
CGCUGAC-3′. Cells were cultured on 6-well plates to
50–75% confluence, transfected with 40 nM siRNA mixed
with G-Fectin (Genolution) for 48 hours, and then ana-
lyzed or treated with drugs.
Analysis of cell viability and apoptosis induction
Cell viability was determined using 3(4,5-dimethyl-thy-
zoyl-2-yl)2,5 diphenyltetrazolium bromide (MTT) and
quantified by absorbance at 595 nm. Percent viability was
determined by comparison with vehicle-treated control
samples. To measure apoptosis, DNA content (propi-
dium iodide or sytox staining), externalized phosphatidyl-
serine (Annexin V) and caspase activation (DEVDase
activity) of the cells were determined using the CaspaTag
in situ apoptosis detection kit (Millipore) and Dead Cell
Apoptosis Kit with Annexin V APC and SYTOX® Green
(Molecular probes). Labeled cells were analyzed using a
FACS Calibur™ flow cytometer (BD Biosciences). Data
were processed using FlowJo software (TreeStar).
Western blot analysis and mitochondrial fractionation
Mitochondrial fractionation from cultured cells was per-
formed with a Mitochondrial Isolation kit (Thermo Sci-
entific) as described in the manufacturer’s instructions.
For western blot analysis, proteins were separated on
8-12% SDS-polyacrylamide gels and transferred to poly-
vinyl difluoride membranes (Millipore). Primary anti-
bodies were diluted 100–5,000-fold, and horseradish
peroxidase-conjugated mouse or rabbit secondary anti-
bodies (KLP Inc.) were diluted 5,000-fold. The ECL re-
agent (GE Healthcare) was used for chemiluminescence
detection with a LAS 4000 imager (GE Healthcare).
Tumor xenograft experiment
All experiments involving animals were approved by the
Ulsan National Institute of Science and Technology Ani-
mal Care and Use Committee (approval number:
UNISTIACUC-12-003-A). Cancer cells (7 × 106 22Rv1 or
1 × 107 MDA-MB-231) were suspended in sterile 200 μl
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flanks of 8-week-old BALB/c nu/nu male mice (Japan SLC
Inc.). MDA-MB-231 cells were orthotopically injected into
the mammary fat pad of 8-week-old BALB/c nu/nu female
mice. Gamitrinib or vehicle (DMSO) dissolved in 20%
Cremophor EL (Sigma) in PBS was injected intraperito-
neally (i.p.), and DOX diluted in PBS was injected intra-
venously (i.v.). The mice were treated with 10 mg/kg
gamitrinib and/or 3 mg/kg DOX twice a week according
to the group. Tumors were measured daily with a caliper
and tumor volume was calculated using the formula V =
1/2 × (width)2 × length. At the end of the experiment the
animals were euthanized, and organs including brain,
heart, kidney, liver, lung, spleen, stomach, intestine, and
testis, and tumors were collected for histologic or west-
ern blot analyses. Blood was also collected for measure-
ment of serum creatine phosphokinase activity using the
Indiko and Konelab System CK (Thermo Scientific) ac-
cording to the manufacturer’s instructions.
RNA extraction and reverse transcript-PCR
Total RNA was prepared from cells suspended in cold
PBS using the RNeasy mini kit (QIAGEN), and cDNA
was synthesized using the ProtoScript® First Strand
cDNA Synthesis Kit (New England Biolabs) using anFigure 1 Combination treatment with DOX and gamitrinib. (A) Gamitr
cells were treated with various concentrations of DOX in the absence (ope
circles), respectively, for 24 hours. Cell viability was analyzed by MTT assay.
DOX-treatment. (B) Effect of combination treatment on cardiomyocytes. M
circles) or presence (closed circles) of 5 μM gamitrinib for 24 hours and ana
(CI) for HeLa cells. The MTT data were analyzed using CalcuSyn software to
standard deviation) is depicted as dotted lines.oligo(dT) primer. The PCR reaction was performed in a
Mastercycler PCR machine (Eppendorf) with the follow-
ing sets of oligonucleotide primers: NOXA, 5′-GTGCC
CTTGGAAACGGAAGA-3′ and 5′-CCAGCCGCCCAG
TCTAATCA-3′; PUMA, 5′-CAGACTGTGAATCCTGT
GCT-3′ and 5′-ACAGTATCTTACAGGCTGGG-3′; DR5,
5′-TGCAGCCGTAGTCTTGATTG-3′ and 5′-GAGTCAA
AGGGCACCAAGTC-3′; Bcl-2, 5′-TTTTAGGAGACCGA
AGTCCG-3′ and 5′-AGCCAACGTGCCATGTGCTA-3′;
Bim, 5′- ATGGCAAAGCAACCTTCTGA-3′ and 5′-GG
AAGCCATTGCACTGAGA-3′; CHOP, 5′-CTTTCTCC
TTCGGGACACTG-3′ and 5′-AGCCGTTCATTCTCTT
CAGC-3′ GAPDH, 5′-GGGAAGCTTGTCATCAATG-3′
and 5′-GCAGTGATGGCATGGACT-3′.Statistical analyses
Data from MTT assay (triplicate experiments independ-
ently repeated at least two times) were averaged and sta-
tistically analyzed by unpaired t-test using Prism 5.0
(GraphPad). A p-value less than 0.05 was considered sig-
nificant. To investigate the synergistic efficacy of the
drug combination, the combination index (CI) was de-
termined according to the Chou-Talalay method using
CalcuSyn software version 2.1 (Biosoft) [23].inib sensitizes cancer cells to DOX treatment. HeLa, SK-OV3, and 22Rv1
n circles) or presence of 5 μM, 10 μM, and 2.5 μM gamitrinib (closed
Percent viability was expressed as a percentage relative to 0 μM
ouse primary cardiomyocytes were treated in the absence (open
lyzed by MTT assay. (C) Graphical representation of combination index
generate CI values. The 95% confidence interval of CI (mean ± 1.96 ×
Table 1 Combination Index (CI) values at ED50 and ED75
in various cancer cell lines
Cell line Origin Drug ratio CI at
ED50
CI at
ED75DOX : Gami
HeLa cervix 1 : 5 0.33 ± 0.03 0.41 ± 0.03
22Rv1 prostate 1 : 10 0.81 ± 0.18 0.53 ± 0.09
A172 brain 1 : 10 0.45 ± 0.28 0.76 ± 0.27
ACHN kidney 1 : 2 0.34 ± 0.11 0.20 ± 0.07
SK-Hep1 liver 1 : 5 0.31 ± 0.05 0.29 ± 0.03
NCI-H460 lung 1 : 5 0.32 ± 0.19 0.45 ± 0.29
SK-OV3 ovary 1 : 1 0.58 ± 0.13 0.95 ± 0.28
MDA-MB-231 breast 5 : 1 0.73 ± 0.27 0.46 ± 0.24
NOTE: Cancer cells were treated with various concentrations of drugs at a
fixed ratio as indicated. CI values at 50% (ED50) and 75% effective doses (ED75)
were calculated from isobologram analysis. Data are the mean ± 1.96 s.d.
(95% confidence interval) of two independent experiments performed
in triplicate.
Figure 2 Induction of apoptosis by combination treatment. (A) Cell de
DOX/2.5 μM gamitrinib and 10 μM DOX/5 μM gamitrinib, respectively, as s
propidium iodide, Sytox, Annexin V staining, and DEVDase activity by flow
Caspase activation by the drug combination. 22Rv1 cells were treated with
blotting. The pan-caspase inhibitor zVAD-fmk was used at a concentration
treatment. 22Rv1 cells were treated with 0.25 μM DOX, 2.5 μM gamitrinib, a
viability compared with DMSO-treated control is shown. Data are the mean
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Gamitrinib-doxorubicin combination treatment showed
synergistic enhancement of cytotoxicity in various cancer
cell lines
To investigate the effect of combination treatment with
DOX and gamitrinib, cancer cell lines originating from
cervix (HeLa), ovary (SK-OV3), and prostate (22Rv1)
were treated with the drugs as single agents or in com-
bination. Gamitrinib sensitized HeLa, SK-OV3, and
22Rv1 cells to a wide range of DOX concentrations
(Figure 1A) and the drug combination resulted in cancer
cell death at suboptimal concentrations (Additional file 1:
Figure S1A). In contrast to the effect on cancer cells,
gamitrinib did not sensitize cardiomyocytes to DOX
treatment (Figure 1B). Next, we calculated the combin-
ation index (CI) using the Chou-Talalay method [23].
The DOX and gamitrinib combination showed synergis-
tic anticancer activity (CI < 0.9) in all cancer cell types
tested at a 50% effective dose: high synergism (CI < 0.7)
for HeLa (Figure 1C), A172 (glioblastoma), ACHN (renalath analysis. 22Rv1 and MDA-MB-231 cells were treated with 0.25 μM
ingle agents or combination treatment for 24 hours, and analyzed for
cytometry. The percentage of cells in each quadrant is indicated. (B)
0.25 μM DOX and 2.5 μM gamitrinib, and analyzed by western
of 10 μM. (C) Effect of caspase inhibitor on the drug combination
nd 10 μM zVAD-fmk as indicated and analyzed by MTT assay. Percent
± SEM of duplicated three independent experiments.
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NCI-H460 (lung carcinoma), and SK-OV-3; and moder-
ate synergism (0.7 < CI < 0.9) for 22Rv1 and MDA-MB-
231 cells (Table 1).Combination of DOX and gamitrinib augments apoptotic
cell death
Single drug treatment at a suboptimal concentration did
not increase caspase activity significantly compared with
the DMSO-treated control, whereas the drug combin-
ation dramatically increased caspase activity and con-
comitant cell death in 22Rv1 and MDA-MB-231 cells
(Figure 2A). Consistently, cell extracts from 22Rv1 and
SK-OV3 showed caspase activation for the combined
drug treatment but not for single agent treatment
(Figures 2B; Additional file 1: Figure S1B). Activation of
caspase by the drug combination was completely inhib-
ited by the pan-caspase inhibitor zVAD-fmk in 22Rv1
(Figure 2B). In addition, the enhanced cytotoxic activity
of the drug combination was significantly abrogated by
zVAD-fmk (Figures 2C; Additional file 1: Figure S1C).
These data suggest that the drug combination activates
caspases and triggers the apoptotic cell death program.Figure 3 Effect of drug combination on the expression of CHOP and
treated with DOX and gamitrinib alone or in combination as indicated and
knockdown. 22Rv1 cells were treated with control or CHOP siRNAs for 24 h
as indicated. The cell viability was analyzed by MTT assay. Data are mean ±
*, p < 0.05; **, p < 0.004. (C) CHOP knockdown and Bim expression. After tre
with DOX and gamitrinib alone or in combination for 24 hours as indicated
combination drug treatment after Bim silencing. After treatment with Bim
gamitrinib for 24 hours as indicated and cell viability was analyzed by MTT
performed in triplicate. *, p < 0.05. (E) Expression of Bcl-2 family proteins an
gamitrinib for 24 hours as indicated. After extraction and reverse transcriptGamitrinib and DOX combination treatment activates
expression of CHOP and Bim
We investigated the effect of combined DOX and gami-
trinib on stress signaling and found that c-Jun N-
terminal kinase (JNK) activation (phosphorylation) and
C/EBP homologous protein (CHOP) induction were in-
creased more by the drug combination than by single
agent treatment in 22Rv1 cells (Figure 3A). Treatment
with CHOP-specific siRNA reduced the enhanced cyto-
toxicity after combined drug treatment but did not affect
cytotoxicity of single agent treatment (Figure 3B),
whereas JNK-specific siRNA did not affect the cytotoxic
activity of the drugs singly or in combination (Additional
file 1: Figure S2A). These data suggest that, in 22Rv1
cells, induction of CHOP is required for the combin-
ation effect of the drugs. As a downstream effector, the
expression of Bim was enhanced by the drug combin-
ation in 22Rv1 cells and knockdown of CHOP compro-
mised the up-regulation of Bim (Figure 3C). Another
prostate cancer cell PC3 similarly showed synergistic in-
duction of cell death and enhanced expression of CHOP
and Bim by the drug combination (Additional file 1:
Figure S2B). DOX alone slightly increased expression of
Bim (Figure 3C; Additional file 1: S2B), which can occurBim. (A) CHOP induction and JNK phosphorylation. 22Rv1 cells were
the whole cell lysate was analyzed by western blotting. (B) CHOP
ours and then with 0.25 μM DOX and 2.5 μM gamitrinib for 24 hours
SEM of two independent experiments performed in triplicate.
atment with control or CHOP-#1 siRNAs, 22Rv1 cells were incubated
and cell extracts were analyzed by western blotting. (D) Effect of
siRNA, 22Rv1 cells were incubated with 0.25 μM DOX and 2.5 μM
assay. Data are mean ± SEM of two independent experiments
d DR5. 22Rv1 cells were treated with 0.25 μM DOX and 2.5 μM
ion of RNA, the cDNA of interest was amplified by PCR.
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reported [24,25]. Inactivation of Bim by siRNA treat-
ment compromised the enhanced cytotoxicity of the
drug combination (Figure 3D). Bim transcription was el-
evated, but expression of other Bcl-2 family proteins,
such as Bcl-2, Puma, and Noxa, was not affected by the
drug combination (Figure 3E). Expression of death re-
ceptor 5 (DR5) was elevated by the drug combination in
a CHOP-dependent manner (Figure 3E) as described
previously [26], while procaspase-8, recruited to the
death inducing signaling complex (DISC) after DR5 acti-
vation [27], was not cleaved at all (Figure 3A). These
data further suggest the crucial role of Bim expression in
the drug combination.
Gamitrinib and DOX combination treatment enhances
mitochondrial localization of Bim and Bax
In contrast to 22Rv1 cells, the drug combination did not
induce CHOP expression in HeLa and MDA-MB-231
cells (Figure 4A). In HeLa cells, knockdown of JNK
compromised the enhanced cytotoxicity of the drug
combination (Figure 4B) whereas knockdown of CHOP
did not affect the drug synergism (Additional file 1:
Figure S2C). These data suggest that there are context-Figure 4 Enhancement of JNK-mediated Bim phosphorylation by dru
and MDA-MB-231 cells were treated with DOX and gamitrinib alone or in c
blotting. (B) JNK silencing compromises the synergistic effect of combinati
treatment with 2 μM DOX and 5 μM gamitrinib as indicated for 24 hours. C
independent experiments performed in triplicate. *, p < 0.02; **, p = 0.0004.
HeLa cells with 5 μM gamitrinib, 2 μM DOX, or 10 μM SP600125 as indicate
(left). Bim phosphorylation in the whole cell extract and the mitochondrial
or Bim-specific siRNAs, HeLa cells were incubated with 2 μM DOX and 5 μM
show mean ± SEM of two independent experiments performed in triplicatedependent disparate stress responses to the drug com-
bination, and the JNK pathway, but not CHOP, can be
critically involved in the synergistic combination effect
in certain cancer cell types. Previous studies have shown
that JNK can activate Bim through phosphorylation to
trigger Bax-dependent mitochondrial apoptosis [28,29].
Phosphorylated Bim was detected in HeLa and MDA-
MB-231 cells, but not in 22Rv1 (Figures 3C and 4A).
Bim protein in HeLa cells was reduced by the drug
combination, but the proteasomal inhibitor MG132
largely elevated the Bim protein level (Additional file 1:
Figure S3A). Similarly, CHOP depletion in the drug
combination was also recovered by MG132 treatment
(Additional file 1: Figure S3A). The data suggest that
turnover rates of CHOP and phosphorylated Bim can be
higher in certain cancer cell types as a result of protea-
somal degradation [30,31]. Treatment with the drug
combination caused increased accumulation of Bim and
Bax in the mitochondria, which was significantly re-
duced by the JNK inhibitor SP600125 (Figure 4C;
Additional file 1: Figure S3B) [32]. The Bim that accu-
mulated in mitochondria was a slow-migrating phospho-
form of the protein (Figure 4C, right panel). The com-
bination effect was compromised by treatment with Bimg combination treatment. (A) Phosphorylation of JNK and Bim. HeLa
ombination for 24 hours as indicated and analyzed by western
on treatment. HeLa cells were treated with JNK siRNA prior to
ell viability was analyzed by MTT assay. Data are mean ± SEM of two
(C) Mitochondrial accumulation of Bim and Bax. After treatment of
d, mitochondria were fractionated and analyzed by western blotting
fraction (right). (D) Effect of Bim silencing. After treatment with control
gamitrinib for 24 hours as indicated and analyzed by MTT assay. Data
. ***, p < 0.0001.
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role of the proapoptotic Bcl-2 protein in the drug-
induced stress response [33].
Drug combination treatment effectively inhibited tumor
growth in vivo without aggravating cardiotoxic side
effects
We examined the anticancer activity of gamitrinib in the
presence of DOX using a prostate cancer xenograft
model with the hormone-independent relapsed humanFigure 5 Drug combination effect in vivo. (A) Prostate cancer xenograft
flanks of nude mouse (5 mice/group). After tumors were established, mice
gamitrinib i.p. as single agents or in combination. (B) Orthotopic xenograft
mammary fat pads of nude mouse (3 mice/group). Mice were treated twic
agents or in combination. (C) Hematoxylin and eosin staining of heart tissu
from the mice and analyzed by hematoxylin and eosin staining. Magnificat
from mice at the end of experiments in (B) and serum creatine phosphoki
in tumor tissue. Tumor samples collected from the xenograft mice in (B) w
mitochondria. Mitochondrial fractionations isolated from the tumors in (B)prostate cancer cell line 22Rv1 [34]. Single treatment
with gamitrinib or DOX resulted in a slight reduction in
tumor volume, whereas combination treatment dramat-
ically suppressed tumor growth (Figure 5A). Because
DOX is frequently used to treat early and metastatic
breast cancers in the clinic [35], we tested the effect of
the drug combination on an orthotopic xenograft model
with the triple negative (lack of ER, PR, and HER2 ex-
pression) metastatic breast cancer cell line MDA-MB-
231 [36]. The tumor growth was strongly inhibited by. 22Rv1 cells (7 × 106 cells) were injected subcutaneously into both
were treated twice a week with 3 mg/kg DOX i.v. and 10 mg/kg
of breast cancer cells. MDA-MB-231 cells (1 × 107 cells) were grown in
e a week with 3 mg/kg DOX i.v. and 10 mg/Kg gamitrinib i.p. as single
es. At the end of the experiment in (B), heart ventricles were collected
ion, 200×. (D) Serum creatine phosphokinase activity. Blood was drawn
nase (CPK) activity was measured. n.s., p > 0.05. (E) JNK phosphorylation
ere analyzed by western blotting. (F) Accumulation of Bim and Bax in
were analyzed by western blotting.
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(Figure 5B). Histologic analysis did not show any prom-
inent differences among the groups (Additional file 1:
Figure S4) except for the heart: a cardiotoxic phenotype
of cytoplasmic vacuolization for DOX alone and in com-
bination treatment (Figure 5C). The serum creatine
phosphokinase (CPK) level was measured as an index
of cardiotoxicity [37] at the end of the experiment
(Figure 5D). DOX treatment alone increased the level of
CPK, but there was no significant further increase in
CPK levels by the drug combination (Figure 5D). These
data suggest that the DOX-induced cardiotoxicity is not
aggravated by the drug combination in vivo. The mech-
anism underlying the activity of the drug combination
in vivo was consistent with the in vitro data: the drug
combination synergistically increased the phosphoryl-
ation of JNK in whole tumor tissue extracts (Figure 5E)
and the accumulation of Bim and Bax in mitochondrial
fractions (Figure 5F).
Discussion
In this study, DOX, one of the most widely used antican-
cer drugs, was combined with the mitochondria-stress
inducer, gamitrinib, to exploit disparate stress pathways
in cancer therapy. Combination of these agents syner-
gistically increased cancer-specific cytotoxic activity
through stimulation of JNK and CHOP stress signaling
pathways and activation of the proapoptotic protein
Bim. Importantly, the drug combination did not aggra-
vate the well-known cardiotoxic side effects of DOX
in vitro or in vivo.
Both gamitrinib [15,16] and DOX [38,39] have previ-
ously been shown to activate JNK and CHOP signaling
pathways. Turning on these stress pathways activates the
proapoptotic Bcl-2 family protein Bim through elevated
gene expression and/or phosphorylation, leading to
mitochondrial cell death [40,41]. As a result of simultan-
eous stimulatory effects on the stress pathways by DOX
and gamitrinib, the drug combination is able to further
increase the amount of Bim protein (through CHOP ele-
vation) and/or mitochondrial accumulation of Bim
(through JNK activation), leading to enhanced mito-
chondrial accumulation of Bax and synergistic induction
of apoptotic cell death.
Combining cancer drugs with disparate mechanisms
of action is a feasible strategy to increase therapeutic ef-
ficacy while avoiding unacceptable side effects of the
drugs [42]. In this regard, combined treatment of DOX
with other cancer drugs has been examined before and
some of these combinations, for example with taxane or
trastuzumab, have shown much more severe cardiotoxic
side effects even at lower cumulative doses [18]. The
combination of DOX and gamitrinib, however, did not
aggravate cytotoxicity to cardiomyocytes in vitro orin vivo. We presume that cardiomyocytes are relatively
resistant to gamitrinib because they are less dependent
on mitochondrial chaperone functions to maintain pro-
tein homeostasis and cope with stresses under normal
physiologic conditions.
Conclusion
In conclusion, combined treatment of DOX and gamitri-
nib showed synergistically enhanced cancer-specific tox-
icity without aggravating cardiotoxic side effects. The
drug combination can realize the full potential of the an-
ticancer activity of the individual drugs and broaden the
application of the drugs to various cancer types.
Additional file
Additional file 1: Figure S1. Drug synergism and apoptosis induction.
Figure S2. Drug combination effect and expression of CHOP, JNK, and
Bim. Figure S3. Effect of MG132 and SP600125. Figure S4. Effects of
drug treatment on normal tissues from xenografted mice.
Competing interest
The authors declare that they have no competing interest.
Authors’ contributions
HKP and BHK participated in design of experiments, data analysis and
interpretation, and manuscript preparation. HKP, JEL, JL, and DEJ participated
in data collection. SAP and PGS provided technical and material support for
animal experiments. All authors read and approved the final manuscript.
Acknowledgements
H.K.P. was supported by a National Junior Research Fellowship from the
National Research Foundation of Korea (NRF-2011-0011833). This work was
supported by the Science Research Center Programs through the National
Research Foundation of Korea (2010–0028684), the Agenda program
(PJ008969) through the Rural Development Administration of Korea, and the
Bio-industry Technology Development program (311006–3) through the
Ministry for Food, Agriculture, Forestry, and Fisheries of Korea. The funders
had no role in study design, data collection and analysis, preparation of the
manuscript, or decision to publish.
Received: 27 January 2014 Accepted: 9 June 2014
Published: 13 June 2014
References
1. Taipale M, Jarosz DF, Lindquist S: HSP90 at the hub of protein
homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010,
11(7):515–528.
2. Trepel J, Mollapour M, Giaccone G, Neckers L: Targeting the dynamic
HSP90 complex in cancer. Nat Rev Cancer 2010, 10(8):537–549.
3. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC: Regulation of
tumor cell mitochondrial homeostasis by an organelle-specific Hsp90
chaperone network. Cell 2007, 131(2):257–270.
4. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO: The
hsp90-related protein TRAP1 is a mitochondrial protein with distinct
functional properties. J Biol Chem 2000, 275(5):3305–3312.
5. Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC:
Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular
target in localized and metastatic prostate cancer. Am J Pathol 2010,
176(1):393–401.
6. Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, Piscazzi A,
Amoroso MR, La Torre G, Esposito F, Landriscina M: Resistance to paclitxel
in breast carcinoma cells requires a quality control of mitochondrial
antiapoptotic proteins by TRAP1. Mol Oncol 2013, 7(5):895–906.
Park et al. BMC Cancer 2014, 14:431 Page 9 of 9
http://www.biomedcentral.com/1471-2407/14/4317. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N, Calabrese F,
Laudiero G, Esposito F, Landriscina M, Defilippi P, Bernardi P, Rasola A: The
mitochondrial chaperone TRAP1 promotes neoplastic growth by
inhibiting succinate dehydrogenase. Cell Metab 2013, 17(6):988–999.
8. Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S,
Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y,
Hasumi H, Xu W, Fukushima H, Nakamura K, Koga F, Kihara K, Trepel J,
Picard D, Neckers L: Molecular chaperone TRAP1 regulates a metabolic
switch between mitochondrial respiration and aerobic glycolysis. Proc
Natl Acad Sci U S A 2013, 110(17):E1604–1612.
9. Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers
JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC,
Languino LR, Speicher DW, Altieri DC: Landscape of the mitochondrial
Hsp90 metabolome in tumours. Nat Commun 2013, 4:2139.
10. Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B,
Neckers L, Altieri DC: Combinatorial drug design targeting multiple
cancer signaling networks controlled by mitochondrial Hsp90. J Clin
Invest 2009, 119(3):454–464.
11. Kang BH, Altieri DC: Compartmentalized cancer drug discovery targeting
mitochondrial Hsp90 chaperones. Oncogene 2009, 28(42):3681–3688.
12. Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB,
Stein GS, Languino LR, Altieri DC: Preclinical characterization of
mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in
advanced prostate cancer. Clin Cancer Res 2010, 16(19):4779–4788.
13. Kang BH, Tavecchio M, Goel HL, Hsieh CC, Garlick DS, Raskett CM, Lian JB,
Stein GS, Languino LR, Altieri DC: Targeted inhibition of mitochondrial
Hsp90 suppresses localised and metastatic prostate cancer growth in a
genetic mouse model of disease. Br J Cancer 2011, 104(4):629–634.
14. Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane
permeabilization in cell death. Physiol Rev 2007, 87(1):99–163.
15. Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, Ross
AH, Plescia J, Altieri DC: Exploiting the mitochondrial unfolded protein
response for cancer therapy in mice and human cells. J Clin Invest 2011,
121(4):1349–1360.
16. Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, Villanueva J,
Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri
DC: Control of tumor bioenergetics and survival stress signaling by
mitochondrial HSP90s. Cancer Cell 2012, 22(3):331–344.
17. Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A,
O’Connell M, Jernigan D, Fatatis A, Languino LR, Bosari S, Altieri DC:
Metabolic stress regulates cytoskeletal dynamics and metastasis of
cancer cells. J Clin Invest 2013, 123(7):2907–2920.
18. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines:
molecular advances and pharmacologic developments in antitumor
activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185–229.
19. Wang JC: DNA topoisomerases. Annu Rev Biochem 1996, 65:635–692.
20. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of
adriamycin cardiotoxicity. Cancer 1973, 32(2):302–314.
21. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M,
Muggia FM: Risk factors for doxorubicin-induced congestive heart failure.
Ann Intern Med 1979, 91(5):710–717.
22. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med
1998, 339(13):900–905.
23. Chou TC: Drug combination studies and their synergy quantification
using the Chou-Talalay method. Cancer Res 2010, 70(2):440–446.
24. Hagenbuchner J, Kuznetsov A, Hermann M, Hausott B, Obexer P,
Ausserlechner MJ: FOXO3-induced reactive oxygen species are regulated
by BCL2L11 (Bim) and SESN3. J Cell Sci 2012, 125(Pt 5):1191–1203.
25. Lopez-Royuela N, Perez-Galan P, Galan-Malo P, Yuste VJ, Anel A, Susin SA,
Naval J, Marzo I: Different contribution of BH3-only proteins and caspases
to doxorubicin-induced apoptosis in p53-deficient leukemia cells.
Biochem Pharmacol 2010, 79(12):1746–1758.
26. Yamaguchi H, Wang HG: CHOP is involved in endoplasmic reticulum
stress-induced apoptosis by enhancing DR5 expression in human
carcinoma cells. J Biol Chem 2004, 279(44):45495–45502.
27. Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY, Hao C:
DR5-mediated DISC controls caspase-8 cleavage and initiation of
apoptosis in human glioblastomas. J Cell Mol Med 2010, 14(6A):1303–1317.
28. Lei K, Davis RJ: JNK phosphorylation of Bim-related members of the Bcl2
family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 2003,
100(5):2432–2437.29. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ,
LaMarche A, Maroney AC, Johnson EM Jr: JNK-mediated BIM
phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003,
38(6):899–914.
30. Hubner A, Barrett T, Flavell RA, Davis RJ: Multisite phosphorylation
regulates Bim stability and apoptotic activity. Mol Cell 2008,
30(4):415–425.
31. Hattori T, Ohoka N, Inoue Y, Hayashi H, Onozaki K: C/EBP family
transcription factors are degraded by the proteasome but stabilized by
forming dimer. Oncogene 2003, 22(9):1273–1280.
32. Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, Leisten JC,
Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW:
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
Proc Natl Acad Sci U S A 2001, 98(24):13681–13686.
33. Youle RJ, Strasser A: The BCL-2 protein family: opposing activities that
mediate cell death. Nat Rev Mol Cell Biol 2008, 9(1):47–59.
34. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS,
Marengo SR, Rhim JS, Zhang D, Jacobberger JW: A new human prostate
carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999, 35(7):403–409.
35. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF,
Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN,
Pusztai L: Response to neoadjuvant therapy and long-term survival in
patients with triple-negative breast cancer. J Clin Oncol 2008,
26(8):1275–1281.
36. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung
MC, Bonfiglio T, Hicks DG, Tang P: The expression patterns of ER, PR,
HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in
breast cancer cell lines. Breast Cancer Basic Clin Res 2010, 4:35–41.
37. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN: Overexpression of
metallothionein in the heart of transgenic mice suppresses doxorubicin
cardiotoxicity. J Clin Invest 1997, 100(6):1501–1506.
38. Kim SJ, Park KM, Kim N, Yeom YI: Doxorubicin prevents endoplasmic
reticulum stress-induced apoptosis. Biochem Biophys Res Commun 2006,
339(2):463–468.
39. Panaretakis T, Laane E, Pokrovskaja K, Bjorklund AC, Moustakas A,
Zhivotovsky B, Heyman M, Shoshan MC, Grander D: Doxorubicin requires
the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun
NH2-terminal kinase to induce apoptosis. Mol Biol Cell 2005,
16(8):3821–3831.
40. Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes
PD, Michalak EM, McKimm-Breschkin J, Motoyama N, Gotoh T, Akira S,
Bouillet P, Strasser A: ER stress triggers apoptosis by activating BH3-only
protein Bim. Cell 2007, 129(7):1337–1349.
41. Ley R, Ewings KE, Hadfield K, Cook SJ: Regulatory phosphorylation of Bim:
sorting out the ERK from the JNK. Cell Death Differ 2005, 12(8):1008–1014.
42. Al-Lazikani B, Banerji U, Workman P: Combinatorial drug therapy for
cancer in the post-genomic era. Nat Biotechnol 2012, 30(7):679–692.
doi:10.1186/1471-2407-14-431
Cite this article as: Park et al.: Combination treatment with doxorubicin
and gamitrinib synergistically augments anticancer activity through
enhanced activation of Bim. BMC Cancer 2014 14:431.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
